Down syndrome
Drug research and approvals for down syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 75 studies of down syndrome are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.
- Recruiting worldwide: 75
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
- Oral Switch in Bloodstream Infections in Immunocompromised ChildrenNCT07923266 · Phase 4 · Copenhagen University Hospital, Rigshospitalet · starts Nov 9, 2026
- Kinematic Analysis of Manual DexterityNCT07875127 · Not reported · IRCCS San Raffaele Roma · starts May 30, 2024
- Effect of Sensory Integration on Gross and Balance on Children With Down SyndromeNCT07785011 · Not applicable · Raheel Sanad · starts Sep 15, 2025
- The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based…NCT07643896 · Not reported · BillionToOne Inc. · starts Jan 10, 2026
- A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease…NCT07636811 · Phase 2 · Alnylam Pharmaceuticals · starts Aug 17, 2026
- Vascular Function in Adults With Down SyndromeNCT07630207 · Not reported · University of Nevada, Las Vegas · starts Apr 9, 2026
- Collaboration for Down Syndrome Progress (CDP)NCT07625579 · Not reported · RTI International · starts May 1, 2026
- Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1NCT07598643 · Phase 2 · University of Colorado, Denver · starts May 28, 2026
- Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal…NCT07493096 · Not reported · Healing Hope International · starts Mar 1, 2026
Phase 3 4
- DonepezilAcetylcholinesterase inhibitor
- Leucovorin
- Thyroid
- DextrothyroxineThyroid hormone receptor agonist
Phase 2 8
- Basmisanil
- Epigalocatechin gallate
- BumetanideSodium-(potassium)-chloride cotransporter 2 inhibitor
- TofacitinibJanus Kinase (JAK) inhibitor
- LorazepamGABA-A receptor; anion channel positive allosteric modulator
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonist
- Scyllitol
Phase 1 or earlier 2
- Insulin glulisineInsulin receptor agonist
- RivastigmineCholinesterases; ACHE & BCHE inhibitor
How its trials ended
356 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 55 whose ending is known, 42% met their primary endpoint, 11% missed it and 47% stopped early.
- Completed, result not reported18251%
- Ongoing7421%
- Status unknown4513%
- Met its primary endpoint236%
- Stopped: other or unclear185%
- Missed its primary endpoint62%
- Stopped: lack of efficacy41%
- Stopped: enrollment or feasibility31%
- Stopped: sponsor or business decision1<1%
| Jan 31, 2025 | A phase 1b study to assess the safety, tolerability, and pharmacokinetics of ION269 in adults with down syndrome and adults with early symptomatic Alzheimer's…ION269 (ION-1620705) | Ionis Pharmaceuticals | Closed |
| Jan 10, 2014 | A multi-center, randomized, double-blind, placebo-controlled phase 2 study of the efficacy, safety and tolerability of RO5186582 in adults and adolescents with…RO5186582 | Roche | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA